Ocular Therapeutix director executes tax share sale

Ocular Therapeutix director and officer Pravin Dugel reported an automatic sale of 20,056 shares of common stock at a weighted average price of $8.28 per share.

Rhea-AI Filing Summary

Ocular Therapeutix director and officer Pravin Dugel reported an automatic sale of 20,056 shares of common stock at a weighted average price of $8.28 per share. According to the disclosure, the transaction was carried out under a durable automatic sale instruction adopted on February 21, 2024 to cover tax withholding obligations tied to restricted stock units vesting on February 22, 2026, and is described as not being a discretionary trade.

After this open-market sale, Dugel directly holds 3,013,022 common shares, and an additional 300,115 shares are reported as held indirectly through the Pravin Dugel 2024 Irrevocable Trust.

Insider Trade Summary

Net Seller: 20,056 shares

Net Sell 2 txns

Insider Dugel Pravin

Role See Remarks

Sold 20,056 shs ($166K)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,056	$8.28	$166K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 3,013,022 shares (Direct); Common Stock — 300,115 shares (Indirect, By Pravin Dugel 2024 Irrevocable Trust)

Footnotes (2)

1. F1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2100 to $8.3700, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

FAQ

What did Pravin Dugel report in the latest OCUL Form 4 filing?

Pravin Dugel reported an automatic sale of 20,056 Ocular Therapeutix shares. The shares were sold at a weighted average price of $8.28 per share to cover tax withholding obligations related to restricted stock units scheduled to vest on February 22, 2026.

Was the OCUL insider share sale by Pravin Dugel a discretionary trade?

The filing states the sale was not a discretionary trade. It was executed under a durable automatic sale instruction adopted on February 21, 2024, specifically to satisfy tax withholding obligations from vesting restricted stock units on February 22, 2026.

How many Ocular Therapeutix (OCUL) shares did Pravin Dugel sell and at what price?

Dugel sold 20,056 common shares at a weighted average price of $8.28. The filing notes these shares were sold in multiple transactions within a price range from $8.21 to $8.37 per share on February 23, 2026.

How many Ocular Therapeutix (OCUL) shares does Pravin Dugel hold after the transaction?

After the sale, Dugel directly owns 3,013,022 OCUL common shares. The filing also reports 300,115 additional shares held indirectly through the Pravin Dugel 2024 Irrevocable Trust, reflecting his reported ownership following the disclosed transaction.

Why were Pravin Dugel’s Ocular Therapeutix (OCUL) shares sold according to the filing?

The shares were sold to cover tax withholding obligations on vesting RSUs. The Form 4 explains that the transaction implemented a prior durable automatic sale instruction tied to restricted stock units vesting on February 22, 2026, rather than a discretionary decision to sell.

What price range did the OCUL insider sale by Pravin Dugel cover?

The reported weighted average price was $8.28 per share. The filing notes the shares were sold in multiple transactions at prices ranging from $8.21 to $8.37, and undertakes to provide detailed breakdowns upon request to the company or regulators.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 06:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dugel Pravin

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S(1)		20,056(1)	D	$8.28(2)	3,013,022	D
Common Stock								300,115	I	By Pravin Dugel 2024 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2100 to $8.3700, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Remarks:

Executive Chairman, President and CEO

	/s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.